Gelsolin amyloidosis (AGel) is characterized by multiple systemic and ophthalmic features resulting from pathological tissue deposition of the gelsolin (GSN) protein. To date, no cure is available for the treatment of any form of AGel. More than ten single-point substitutions in the GSN gene are responsible for the occurrence of the disease and, among them, D187N/Y is the most widespread variant. These substitutions undergo an aberrant proteolytic cascade, producing aggregation-prone peptides of 5 and 8 kDa, containing the Gelsolin Amyloidogenic Core, spanning residues 182–192 (GAC182–192). Following a structure-based approach, we designed and synthesized three novel sequence-specific peptidomimetics (LB-5, LB-6, and LB-7) built on a piperidine-pyrrolidine unnatural amino acid. LB-5 and LB-6, but not LB-7, efficiently inhibit the aggregation of the GAC182–192 amyloidogenic peptides at sub-stoichiometric concentrations. These peptidomimetics resulted also effective in vivo, in a C. elegans-based assay, in counteracting the proteotoxicity of aggregated GAC182–192. These data pave the way to a novel pharmacological strategy against AGel and also validate a toolbox exploitable in other amyloidogenic diseases.
1 October 2019 in Biochemical and Biophysical Research Communications
Hereditary gelsolin amyloidosis (AGel) is a rare and often underrecognized protein misfolding disorder caused by mutations in the gelsolin (GSN) protein, leading to its aggregation in various tissues. Its rarity, combined with a heterogeneous and complex clinical presentation and the multidomain, flexible nature of GSN, has impeded research into its pathogenic mechanisms and therapeutic options. GSN comprises six homologous domains, labeled sequentially from G1 to G6. For over 40 years, AGel amyloidosis was exclusively linked to a systemic form, caused by D187N and D187Y mutations in the second domain, referred to as the Finnish and Danish variants. However, since 2013, numerous novel amyloidogenic variants have been identified in different protein regions, leading to various clinical phenotypes, characterized by distinct molecular mechanisms. This review examines these mutations and proposes a classification based on molecular and clinical features to enhance research and diagnosis. Additionally, we summarize whether elucidating the different pathogenic mechanisms aids in identifying potential druggable targets. The lack of information and biological models and limited efforts to develop pharmacological treatments highlight the need for further therapeutic exploration.
Protein–protein interactions (PPIs) have been recognized as a promising target for the development of new drugs, as proved by the growing number of PPI modulators reaching clinical trials. In this context, peptides represent a valid alternative to small molecules, owing to their unique ability to mimic the target protein structure and interact with wider surface areas. Among the possible fields of interest, bacterial PPIs represent an attractive target to face the urgent necessity to fight antibiotic resistance. Growing attention has been paid to the YgjD/YeaZ/YjeE complex responsible for the essential t6A37 tRNA modification in bacteria. We previously identified an α‐helix on the surface of Pseudomonas aeruginosa YeaZ, crucial for the YeaZ‐YeaZ homodimer formation and the conserved YeaZ‐YgjD interactions. Herein, we present our studies for impairing the PPIs involved in the formation of the YeaZ dimers through synthetic peptide derivatives of this helical moiety, both in vitro with purified components and on P. aeruginosa cells. Our results proved the possibility of targeting those PPIs which are usually essential for protein functioning and thus are refractory to mutational changes and antibiotic resistance development.
Small-angle X-ray and neutron scattering (SAXS/SANS) provide valuable information on biomolecules in solution and are particularly well-suited to complement a wide range of structural techniques, including molecular dynamics simulations. As contrast-based techniques, they are sensitive not only to structural properties but also to the solvent-solute interactions. Their use in molecular dynamics simulations requires a forward model that should be as fast and accurate as possible. Here we show that it is possible to calculate SAXS and SANS using a coarse-grained representation of one bead per amino acid and three beads for nucleic acid with form factors that can be corrected on-the-fly to account for their interaction with the solvent at no additional computational cost. We use SAXS data measured for the closed state of Gelsolin and previous data for a UP1-microRNA complex to show that such approach allows to refine the structure and dynamics of proteins and nucleic acids. Our hybrid resolution small angle scattering (hySAS) implementation, being distributed in PLUMED, is ready to be coupled with atomistic and coarse-grained simulations using diverse restraining strategies.